Literature DB >> 18752646

The blood-cerebrospinal fluid barrier is a major pathway of cerebral creatinine clearance: involvement of transporter-mediated process.

Masanori Tachikawa1, Yasuyuki Kasai, Masato Takahashi, Jun Fujinawa, Kiyoyuki Kitaichi, Tetsuya Terasaki, Ken-Ichi Hosoya.   

Abstract

There is still incomplete evidence for the cerebral clearance of creatinine (CTN) which is an endogenous convulsant and accumulates in the brain and CSF of patients with renal failure. The purpose of this study was to clarify the transporter-mediated CTN efflux transport from the brain/CSF. In vivo data demonstrated that CTN after intracerebral administration was not significantly eliminated from the brain across the blood-brain barrier. In contrast, the elimination clearance of CTN from the CSF was 60-fold greater than that of inulin, reflecting CSF bulk flow. Even in renal failure model rats, the increasing ratio of the CTN concentration in the CSF was lower than that in the plasma, suggesting a significant role for the CSF-to-blood efflux process. The inhibitory effects of inhibitors and antisense oligonucleotides on CTN uptake by isolated choroid plexus indicated the involvement of rat organic cation transporter 3 (rOCT3) and creatine transporter (CRT) in CTN transport. rOCT3- and CRT-mediated low-affinity CTN transport with K(m) values of 47.7 and 52.0 mM, respectively. Our findings suggest that CTN is eliminated from the CSF across the blood-CSF barrier as a major pathway of cerebral CTN clearance and transporter-mediated processes are involved in the CTN transport in the choroid plexus.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752646     DOI: 10.1111/j.1471-4159.2008.05641.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  13 in total

Review 1.  Inner blood-retinal barrier transporters: role of retinal drug delivery.

Authors:  Ken-ichi Hosoya; Masanori Tachikawa
Journal:  Pharm Res       Date:  2009-07-01       Impact factor: 4.200

Review 2.  Roles of organic anion/cation transporters at the blood-brain and blood-cerebrospinal fluid barriers involving uremic toxins.

Authors:  Ken-ichi Hosoya; Masanori Tachikawa
Journal:  Clin Exp Nephrol       Date:  2011-05-25       Impact factor: 2.801

Review 3.  Neuroimmune Axes of the Blood-Brain Barriers and Blood-Brain Interfaces: Bases for Physiological Regulation, Disease States, and Pharmacological Interventions.

Authors:  Michelle A Erickson; William A Banks
Journal:  Pharmacol Rev       Date:  2018-04       Impact factor: 25.468

4.  Disease-related changes in the cerebrospinal fluid metabolome in amyotrophic lateral sclerosis detected by GC/TOFMS.

Authors:  Anna Wuolikainen; Thomas Moritz; Stefan L Marklund; Henrik Antti; Peter Munch Andersen
Journal:  PLoS One       Date:  2011-04-04       Impact factor: 3.240

5.  Transport characteristics of guanidino compounds at the blood-brain barrier and blood-cerebrospinal fluid barrier: relevance to neural disorders.

Authors:  Masanori Tachikawa; Ken-Ichi Hosoya
Journal:  Fluids Barriers CNS       Date:  2011-02-28

Review 6.  Amyotrophic Lateral Sclerosis and Metabolomics: Clinical Implication and Therapeutic Approach.

Authors:  Alok Kumar; Devlina Ghosh; R L Singh
Journal:  J Biomark       Date:  2013-03-14

7.  Role of cationic drug-sensitive transport systems at the blood-cerebrospinal fluid barrier in para-tyramine elimination from rat brain.

Authors:  Shin-Ichi Akanuma; Yuhei Yamazaki; Yoshiyuki Kubo; Ken-Ichi Hosoya
Journal:  Fluids Barriers CNS       Date:  2018-01-08

Review 8.  A proposed role for efflux transporters in the pathogenesis of hydrocephalus.

Authors:  Satish Krishnamurthy; Michael D Tichenor; Akhila G Satish; David B Lehmann
Journal:  Croat Med J       Date:  2014-08-28       Impact factor: 1.351

Review 9.  The Impact of Uremic Toxins on Cerebrovascular and Cognitive Disorders.

Authors:  Maryam Assem; Mathilde Lando; Maria Grissi; Saïd Kamel; Ziad A Massy; Jean-Marc Chillon; Lucie Hénaut
Journal:  Toxins (Basel)       Date:  2018-07-22       Impact factor: 4.546

10.  Cross-sectional analysis of plasma and CSF metabolomic markers in Huntington's disease for participants of varying functional disability: a pilot study.

Authors:  Andrew McGarry; John Gaughan; Cory Hackmyer; Jacqueline Lovett; Mohammed Khadeer; Hamza Shaikh; Basant Pradhan; Thomas N Ferraro; Irving W Wainer; Ruin Moaddel
Journal:  Sci Rep       Date:  2020-11-24       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.